These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1019 related articles for article (PubMed ID: 26503995)

  • 1. Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
    Dempke WC; Sellmann L; Fenchel K; Edvardsen K
    Anticancer Res; 2015 Nov; 35(11):5745-57. PubMed ID: 26503995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing the unmet need in lung cancer: The potential of immuno-oncology.
    Scagliotti GV; Bironzo P; Vansteenkiste JF
    Cancer Treat Rev; 2015 Jun; 41(6):465-75. PubMed ID: 25936526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
    Anagnostou VK; Brahmer JR
    Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
    Langer CJ
    Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint modulation for non-small cell lung cancer.
    Soria JC; Marabelle A; Brahmer JR; Gettinger S
    Clin Cancer Res; 2015 May; 21(10):2256-62. PubMed ID: 25979932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
    Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):557-69. PubMed ID: 25253438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
    Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.
    Melosky B; Chu Q; Juergens R; Leighl N; McLeod D; Hirsh V
    J Clin Oncol; 2016 May; 34(14):1676-88. PubMed ID: 26884577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.
    Gridelli C; Ascierto PA; Barberis MC; Felip E; Garon EB; O'brien M; Senan S; Casaluce F; Sgambato A; Papadimitrakopoulou V; De Marinis F
    Expert Opin Biol Ther; 2016 Dec; 16(12):1479-1489. PubMed ID: 27650132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Huang J; Reckamp KL
    Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.
    Rolfo C; Caglevic C; Santarpia M; Araujo A; Giovannetti E; Gallardo CD; Pauwels P; Mahave M
    Adv Exp Med Biol; 2017; 995():97-125. PubMed ID: 28321814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
    Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
    Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
    Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
    Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
    Marrone KA; Brahmer JR
    Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.
    Valecha GK; Vennepureddy A; Ibrahim U; Safa F; Samra B; Atallah JP
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):47-59. PubMed ID: 27841044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management.
    Sgambato A; Casaluce F; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
    Curr Drug Saf; 2016; 11(1):62-8. PubMed ID: 26412670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
    Kumar R; Collins D; Dolly S; McDonald F; O'Brien MER; Yap TA
    Curr Probl Cancer; 2017; 41(2):111-124. PubMed ID: 28214087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome.
    Shepherd FA; Douillard JY; Blumenschein GR
    J Thorac Oncol; 2011 Oct; 6(10):1763-73. PubMed ID: 21876456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.